The measurement of hemoglobin A 1c (HbA 1c ) 17 in human blood is the most important marker for long-term assessment of the glycemic state in patients with diabetes, and goals for therapy are set at specific HbA 1c target values (1) (2) (3) (4) . There are many commercial methods available for the routine measurement of HbA 1c . These methods are based on different analytical principles, such as immunoassays, ion-exchange chromatography, and affinity chromatography. Several surveys (5) (6) (7) (8) have demonstrated that different results are produced by these different method principles. However, therapeutic targets for patients with diabetes require method-independent values for HbA 1c . Furthermore, if in the future HbA 1c is to be used for the diagnosis of diabetes or impaired glucose tolerance, it is essential that the different HbA 1c methods used routinely in medical laboratories provide comparable results.
Studies have shown that harmonization of test results obtained by different HbA 1c assays is feasible if all of the methods are calibrated with the same set of calibrators (9, 10 ) and/or are adjusted to a Designated Comparison Method (DCM) (11 ) . These principles have been used in national initiatives for the harmonization of HbA 1c results. In the US, the National Glycohemoglobin Standardization Program (NGSP) has been established (12 ) . The Japanese Diabetes Society (JDS) developed a set of national calibrators with the recommendation to adjust the calibration of all routine HbA 1c methods to these calibrators (13 ) . In Sweden, the Mono S method, a high-resolution ion-exchange HPLC method, has been chosen as the DCM for the harmonization of HbA 1c results (14 ) . All of these national initiatives were important steps toward improvement of the comparability of HbA 1c test results, but national standardization programs based on different DCMs cannot replace uniform worldwide standardization anchored on a metrologically sound international reference measurement system (15, 16 ) comprising (a) a clear definition of the analyte based on its molecular structure, (b) a primary reference material containing the analyte in a pure form, (c) a validated reference method that specifically measures the analyte in human samples, and (d) a global network of reference laboratories that guarantees that the reference method is performed with the necessary analytical quality and is capable of assigning reliable values to matrix-based secondary reference materials and calibrators.
The IFCC Working Group on HbA 1c Standardization has developed such a reference system for HbA 1c (17 ) . HbA 1c is defined as the stable adduct of glucose to the N-terminal valine of the ␤-chain of Hb. Primary reference materials of pure HbA 1c and HbA 0 have been prepared (18 ) , and a reference method that specifically measures HbA 1c has been developed (19, 20 ) . The reference method has been approved by all member national societies of the IFCC, and a global network of reference laboratories has been established (20, 21 ) .
When the IFCC Reference Method for the calibration of HbA 1c routine methods is used, laboratorians must consider that the current clinical interpretation of HbA 1c results is based on data from tests that were calibrated to DCMs that were less specific than the IFCC Reference Method and therefore generated HbA 1c values that are higher than those that will be obtained if the calibration is traced back to the IFCC Reference Method. To ensure the proper clinical use of the tests, it is important to understand the numeric relationship between the IFCC Reference Method and the DCMs used in the national standardization schemes. This study was designed to investigate this relationship.
Materials and Methods ifcc reference method
The reference method was developed as candidate reference method by Kobold et al. (19 ) (20 ) . A PDF version of the method can be downloaded free of charge from the IFCC section of Clinical Chemistry and Laboratory Medicine (www.degruyter.de/ journals/cclm/pdf/401_78.pdf).
The IFCC Reference Method has three steps. In the first step, Hb from washed and lysed erythrocytes is cleaved into peptides by the proteolytic enzyme endoproteinase Glu-C. The resulting glycated and nonglycated N-terminal hexapeptides of the ␤-chain are then separated from the crude peptide mixture by reversed-phase HPLC. In the third and final step, the glycated and nonglycated hexapeptides are quantified by mass spectrometry or by capillary electrophoresis with ultraviolet detection. The percentage of HbA 1c is determined by the ratio of glycated to nonglycated ␤-N-terminal hexapeptides of Hb.
The measurements in this study were performed by the reference laboratories of the IFCC Network of Reference Laboratories (IFCC-NRL), which are listed in the Appendix. The network comprises laboratories from Europe, Japan, and the US that have successfully established the reference method. The network is coordinated by the Network Coordinator, who is responsible for the organization of meetings, updating the Standard Operating Procedure of the reference method, and organizing regu-lar quality-control surveys within the network. The network works on behalf of, and is supervised by, the IFCC Working Group on HbA 1c Standardization (21 ) .
ngsp standardization scheme
The NGSP system was established after the Diabetes Control and Complications Trial (DCCT) study showed the relationship between HbA 1c and risks for development and/or progression of diabetes complications. Implementation of treatment goals based on the results of the DCCT in clinical settings made it necessary to harmonize HbA 1c results (22 ) . The anchor for the NGSP laboratory network is a DCM, which is ion-exchange HPLC using Bio-Rex 70 resin (Bio-Rad Laboratories) (23 ) . The method is performed in the Central Primary Reference Laboratory (CPRL) and backup Primary Reference Laboratories (PRLs) (12 ) . Secondary Reference Laboratories (SRLs) have been established to assist manufacturers with calibration to the DCCT as well as serving as the comparison methods for NGSP certification. These laboratories use HbA 1c assay methods of various method types (ionexchange HPLC, affinity HPLC, and immunoassay) that are convenient and robust, provide excellent analytical performance, and are calibrated to the CPRL method. The CPRL, PRLs, and SRLs work closely together in a network of reference laboratories (NGSP-NRL). The network laboratories are monitored monthly by sample exchanges with the CPRL. The "NGSP-HbA 1c values" in this study were measured by the SRLs located in the US and Europe.
jds/jscc standardization scheme
The basis of the JDS/JSCC standardization scheme are national calibrators. In 1995, the JDS developed a first set of national calibrators, called JDS Calibrator Lot 1, which was recommended to be used for the calibration of all routine HbA 1c assays in Japan. The calibrator values were assigned with the HPLC ion-exchange chromatography methods of TOSOH and Kyoto Daiichi. These two methods were chosen because at the time when the calibrators were established, most of the Japanese medical laboratories used one of these HPLC methods. In recent years the Japanese standardization scheme has evolved. The Japanese Society of Clinical Chemistry (JSCC) developed a high-resolution ion-exchange HPLC method, named KO500 (24 ) , and a second set of national calibrators (deep-frozen blood), called JDS/JSCC Calibrator Lot 2. The KO500 method was used to assign target values to the Lot 2 calibrators and to samples for national proficiency testing. To keep consistency in the HbA 1c values, the calibration of the KO500 method was adjusted to the first lot of JDS calibrators. For the measurements in this study, the KO500 HPLC method was calibrated with JDS Calibrator Lot 2. The measurements were performed by the three Japanese IFCC reference laboratories, which are also reference laboratories of the JDS/JSCC standardization scheme.
swedish standardization scheme
The Swedish standardization scheme uses the Mono S method (strong methylsulfonate cation exchanger on monobeads; Amersham Biosciences) as DCM for the harmonization of HbA 1c measurements (25 ) . The measurements in this study were performed by the Swedish IFCC reference laboratory at the Malmo University Hospital. The laboratory is a part of the EQAS organization, External Quality Assurance in Laboratory Medicine in Sweden (EQUALIS), located in Uppsala. Split samples of fresh EDTA blood are distributed once a month to 40 hospitals using different HPLC methods. Five of them are contracted to run the Mono S system in a national network. These laboratories are used for calibration of all hospital and point-of-care instruments in Sweden every second year.
design and logistics
The study was designed by the IFCC Working Group on HbA 1c Standardization and organized logistically by the IFCC reference laboratory in Winterswijk (The Netherlands), which currently holds the function of the IFCC Network Coordinator, and the reference laboratory in Zwolle (The Netherlands), which was responsible for the blood collection. The design was adjusted to the aim of the study, which was to generate equations that describe reliably the relationship between the various reference systems. Therefore, low uncertainty of the resulting equations as well as an acceptable workload for the reference laboratories performing the measurements had to be considered. The uncertainty of the equations depends on many factors, such as the analytical performance of the measurements, the number of measurements per sample, systematic differences between the laboratories within the networks, the number of participating laboratories per system, the number of samples analyzed, the biological variation of samples, and the number of measurement campaigns (covering shifts attributable to changes in calibration, reagents, and instruments). To evaluate all factors that contribute to the uncertainty and to reduce the overall uncertainty, blood pools were used instead of single samples (explanation see below). The results among networks and not among laboratories were compared, each specimen was measured four times by each laboratory, and the experiments were repeated in four independent studies. The studies were samples When evaluating the quantitative relationship between the reference systems, the biological variation in the samples used for the method comparison is a major confounding factor. The biological variation results from the fact that the composition of blood in each individual is slightly different. There are Hb derivatives such as carbamylated Hb and other adducts, and Hb forms that may interfere with the NGSP-SRL methods in particular; these are commercial methods with a broad spectrum of method principles (ion-exchange chromatography, immunoassays, affinity chromatography) (26 ) . Theoretically, the influence of biological variation should be substantially reduced if the samples used are mixtures of blood from various donors rather than samples derived from single donors. This hypothesis was checked and confirmed to be true in a separate study in which 36 donations were used to prepare 36 single specimens as well as 6 pools (each pool being a mixture of 6 individual donations), and HbA 1c was measured by the network laboratories. The outcome was that the HbA 1c values of the pools were not significantly different from the mean of the HbA 1c values of the respective single donations (mean of singles, 6.84%; mean of mixtures, 6.85%; P Ͼ0.999) and that the intralaboratory CV were the same for pools and singles donations (combined CV for singles 1.1%; for mixtures 1.1%; P Ͼ0.999), but the scatter of the HbA 1c values around the regression line characterized by S y͉x was significantly lower for pools than for single donations (e.g., for the relationship of the IFCC-NRL and the NGSP-NRL, S y͉x was 0.17 for single donations and 0.08 for pools, respectively). This means that use of blood pools could substantially reduce the uncertainty of the resulting regression equations. Therefore, the blood pools used in this study were as follows: in the Marrakech study, eight samples in the range 3.04 -9.65%; in the Chicago study, eight samples in the range 3.30 -9.00%; in the Kyoto I study, five samples in the range 3.09 -11.25%; and in the Kyoto II study, five samples in the range 3.48 -8.65% HbA 1c (HbA 1c percentages determined by the IFCC Reference Method). Each sample was prepared from 10 donations.
Before mixing, each donation was checked for (a) hepatitis B surface antigen, anti-HIV, and anti-hepatitis C antibodies (Abbott Laboratories; criterion, samples must be negative); (b) abnormal Hb variants such as S, C, E, and F (Menarini 8140 method; A.Menarini; criterion, HbF Ͻ1% and other variants absent); and (c) abnormal amounts of urea to exclude increased concentrations of carbamylated Hb. The HbA 1c value was used to make pools with appropriate HbA 1c concentrations. The blood samples (60 -90 donations for each campaign) were drawn and checked within a time frame of 32 h. Donations were stored in the refrigerator (2-8°C) until pools were prepared. The pools were the starting material to supply both IFCC network laboratories and DCMs with specimens (described below).
specimens for the ifcc reference method
Both whole blood and hemolysates are suitable materials for the IFCC Reference Method and provide the same numerical HbA 1c results. This was demonstrated during the development of the reference method: a panel of whole-blood samples and hemolysates from the same blood were measured in parallel, and identical results were obtained [regression equation: y ϭ 1.006x Ϫ 0.035% HbA 1c ; r 2 ϭ 0.999; slope and the intercept did not deviate significantly from 1 (P Ͼ0.999) and 0 (P Ͼ0.99), respectively]. However, whole blood is stable for ϳ1 week, whereas hemolysates stored at Ϫ70°C are stable for many years (e.g., a hemolysate manufactured in 1999 and measured by the IFCC-NRL in 1999, 2001, and 2002 had HbA 1c values of 9.39%, 9.37%, and 9.32%, respectively). Because the IFCC Reference Method is time-consuming and the reference laboratories are spread globally, there was a need to have a time buffer for shipment and performing the measurements. Therefore, frozen hemolysates were used in this study. The hemolysates were prepared from the blood pools according to the Standard Operating Procedure of the IFCC Reference Method (20 ) within 32 h after blood drawing and stored at Ϫ70°C until shipment. The samples were shipped on dry ice (Ϫ79°C; amount sufficient for 5 days) by courier to the IFCC-NRL laboratories. The reference laboratories checked for the presence of dry ice, which was still present when the samples arrived at all laboratories during all studies, and stored the samples at Ϫ70°C until analysis. The measurements were performed within 9 weeks of hemolysate preparation.
specimens for the DCMs
All of the DCMs work with hemolysates, but the methods use different hemolyzing agents and different dilutions. Therefore, whole-blood specimens were sent to the DCM laboratories, which were prepared locally for the measurement according to the specific protocol of the DCM used. Blood from the pools was dispensed in 1-mL aliquots, packed in special isolating boxes on cool packs (2-8°C; capacity 4 days) within 8 h after preparation of the pools, and immediately shipped by courier. On arrival, the DCM laboratories checked the temperature and stored the specimens until the measurement. All measurements were performed within 5 days after blood drawing.
quality control
A precondition for the inclusion of the results of the IFCC network laboratories was that they had successfully passed the regular quality-control surveys of the IFCC-NRL. The IFCC-NRL control surveys were organized twice a year. Six hemolysates with HbA 1c concentrations covering the clinically relevant concentration range (3-13% HbA 1c ) were distributed to the network laboratories, and each sample was measured four times by the reference laboratories. The criteria for passing were that the mean intralaboratory CV was Յ2.5% and the mean deviation from the overall mean of all NRL laboratories was Յ2.5%. The mean intralaboratory CV of the NRL laboratories in the surveys performed during this study was 1.0 -1.2%, the intralaboratory CV varied from 0.50% to 2.2%, and the interlaboratory CV were in the range of 1.4 -1.9%. In two studies, one reference laboratory did not The laboratories of the NGSP-NRL participated in a monthly monitoring program with specific precision and bias limits (12 ) . All laboratories met the requirements of the program during the time of the method-comparison studies (mean difference between CPRL and SRL HbA 1c values Ͻ0.35%; SD of difference replicates Ͻ0.23%).
The JDS/JSCC-NRL laboratories twice a year exchanged a set of samples (deep-frozen blood) with five HbA 1c concentrations (4.05-12.63%) and participated in the IFCC/DCM trials. The interlaboratory CV in these studies were Ͻ1.0%.
The Swedish reference laboratory participated in the national network of Mono S reference laboratories, which performed regular intercomparison studies. Split samples of fresh EDTA blood were distributed once a month. The interlaboratory CV in this Mono S network intercomparison studies were Ͻ1.5%.
statistical evaluation
The mean values of the four measurements per sample and the SDs and CV for these measurements were calculated for each individual laboratory. The mean values of the laboratories were used to calculate the "overall mean values " of the IFCC-NRL, the NGSP-NRL, and the JDS/JSCC-NRL. The overall mean values were used as "IFCC-HbA 1c values", "NGSP-HbA 1c values", "JDS/ JSCC-HbA 1c values", and "Swedish-HbA 1c values" for the calculation of the relationship between the IFCC reference system and the DCM-based systems. Each of the four method-comparison studies was evaluated separately. Whether the correlation between the IFCC Reference Method and the DCMs fits a linear regression model was checked by visual inspection. Because this could be confirmed for all comparisons, linear regression analysis was used for calculating slopes, intercepts, and r 2 , with use of SAS software, Ver. 8.2 (SAS Institute). The SAS software was also used to apply the Kruskal-Wallis test to check whether there were statistically significant differences in the outcomes of the four studies. Finally, the results of the four studies were combined, and the overall regression equations were calculated for the correlation between the DCM-based systems and the IFCC reference system. The presence of statistically significant differences between the system values was checked, as indicated by the slope deviating statistically significantly from 1 and/or the intercept from 0, respectively.
Results
The mean intralaboratory CV in the four studies was 1.1% (range, 0.38 -2.1%) for the 11 laboratories of the IFCC-NRL; 1.0% (range, 0.47-2.4%) for the 9 SRLs of the NGSP; 0.54% (0.27-0.87%) for the three Japanese reference laboratories, and 0.57% (0.30 -0.58%) for the Swedish reference laboratory. The mean interlaboratory CV were 1.9% for the IFCC-NRL, 1.9% for the NGSP-NRL, and 0.66% for the JDS/JSCC-NRL. The slopes and intercepts of the regression equations and the r 2 for the relationship between the IFCC-HbA 1c values and the DCM-HbA 1c values of the four studies are listed in Table 1 . The KruskalWallis test demonstrated that there were no statistically significant differences in the outcomes of the four studies [IFCC-NRL, 2 ϭ 0.70 (P ϭ 0.87); NGSP-NRL, 2 ϭ 0.83 (P ϭ 0.84); JDS/JSCC-NRL, 2 ϭ 0.90 (P ϭ 0.82); Swedish-RL, 2 ϭ 0.88 (P ϭ 0.83)] so that the results of the four studies could be combined to calculate the overall regression equations ( Table 2 ). The slope and the intercept of the equation for the IFCC vs NGSP methods deviated significantly from 1 and 0, respectively (P Ͻ0.001). However, the relationship between the two systems was linear, and there was very little dispersion of the measured values around the regression line (r 2 ϭ 0.998; see Fig. 1 ). There were also statistically significant differences between the IFCC-HbA 1c values and the JDS/JSCC-HbA 1c values. However, as with the NGSP, there was a strong linear correlation between both systems (r 2 ϭ 0.997; see Fig. 2 ). There was a slightly higher variation in the outcome of the four method-comparisons studies of the IFCC-NRL vs the Swedish-RL, but the differences were not statistically significant. The higher random variation was attributable to the HbA 1c values from the Swedish standardization scheme not being the mean values of a network of reference laboratories but rather the results from one laboratory. In contrast to the two other systems, the overall slope of 0.989 did not deviate significantly from 1 (P Ͼ0.95; see Fig. 3 ), whereas the intercept was significantly different from 0 (P Ͻ0.001).
There were also statistically significant differences in the slopes as well in the intercepts between the three DCM-based systems (Table 3) .
Discussion
To ensure optimum quality of patient care and a valid interpretation of clinical trials, good interlaboratory agreement of results in laboratory medicine is essential. The most effective approach for achieving universal comparability of test results is the ability to trace the calibration of the routine assays back to an international metrologically sound reference measurement system. Therefore, an essential requirement of the IVD Directive of the European Union is that manufacturers have to trace back the calibration of their tests to reference methods or reference materials of higher metrologic order if available (27 ) .
With the development of the IFCC reference system, a reference method and reference materials of higher metrologic order are now available for the measurement of HbA 1c . In the IFCC reference system, HbA 1c is defined on its molecular structure and specifically measured with a reference method, whereas in the existing DCM-based national standardization schemes HbA 1c is defined and measured as the "HbA 1c " peak of the chromatogram of the chosen DCM. These HbA 1c peaks contain not only HbA 1c but also, depending on the resolution of the resin used, to some extent substances that are not HbA 1c (28 -32 ) . To minimize the confounding effect of biological variation, blood pools were used as samples in this study, and blood with abnormal Hb variants such as S, C, E, and F and abnormal urea concentrations (carbamylated Hb) were excluded.
Considering the lack of specificity of the DCMs, it is not surprising that all three DCMs generate significantly higher results than the IFCC Reference Method and that there are significant differences among the results of the three DCMs as well (see Table 3 ). The NGSP-SRL generates the highest HbA 1c values because the HbA 1c peak of the Bio-Rex 70 method, used as anchor of the NGSP, contains a high proportion of non-HbA 1c substances, such as HbF, minor Hb forms, and carbamylated Hb, and the peak is not clearly separated from the neighboring nonHbA 1c peaks (23 ) . The KO500 used in the Japanese scheme is a high-resolution HPLC method, but because this method is based on calibrators with values that were assigned with the older HPLC methods from TOSOH and Kyoto Daiichi, the JDS/JSCC-NRL values reflect the low specificities of these methods. The results of the JDS/ JSCC-NRL are slightly lower than those of the NGSP-NRL. The Swedish DCM generates the lowest DCM HbA 1c values. The Mono S system, developed in 1983, shows an almost homogeneous HbA 1c peak in the chromatogram, but it contains carbamylated Hb as well as free ␣-globulin chains (25, 31, 32 ) , so that the values are higher than those measured with the IFCC Reference Method. In contrast to the DCM methods, new dedicated HPLC systems are today eliminating many of these interfering adducts such as carbamylated Hb by use of more modern chromatographic material and improved gradients (33 ) .
There is, however, a strong correlation between the IFCC values and the DCM values, which can be described by a linear regression model. The relationships were identical in all four studies, and the dispersion of the values around the regression line was small. It is therefore possible to establish reliable numerical links between the results of the IFCC Reference Method and the DCMs described by linear regression equations. When calibrators with IFCC values are used, the HbA 1c values of the routine methods will be lower than those generated with the previous calibration. There are significant numerical differences between HbA 1c values based on the IFCC Reference Method calibration and HbA 1c values based on the DCM calibrations (see Table 4 ). These changes are similar to the change in glucose values four decades ago when the nonspecific glucose routine methods, based on the measurement of the reduction caused by glucose and other substances in blood, were replaced by methods that specifically measured glucose (34, 35 ) . Because of the close correlation between the IFCC Reference Method and the DCMs, it is possible to derive IFCC values from the existing scales of numbers by use of linear regression equations. Because the Bio-Rex 70 method was used as reference for harmonization of the HbA 1c test results in the DCCT study (1 ) , it is also possible to "translate" the risk curves generated in this landmark study and the HbA 1c data of the important UKPDS study (2 ) , which were also adjusted to the Bio-Rex 70 calibration. When regression equations are used for transforming IFCC HbA 1c values into DCM HbA 1c values and vice versa, the additional uncertainty introduced by the uncertainty of the regression equations must be considered. This uncertainty must be added to the uncertainty of the analytical measurement. The uncertainty values given in Table 4 were calculated according to the Eurochem/Citac Guide for Quantifying Uncertainty in Analytical Measurement (36 ) , considering the IFCC value as independent variable. The standard uncertainty is the standard error of the predicted DCM value.
Changing medical decision criteria is not just a matter for laboratory professionals but also for the healthcare providers and patients who use these criteria. Therefore, the IFCC Working Group on HbA 1c Standardization has contacted the international scientific societies of diabetologists to discuss appropriate ways of adopting the IFCC standardization for HbA 1c routine tests in clinical practice.
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